Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection

被引:9
作者
Wilkinson, Royce A. [1 ]
Pincus, Seth H. [2 ,3 ]
Song, Kejing [2 ]
Shepard, Joyce B. [1 ]
Weaver, Alan J., Jr. [1 ]
Labib, Mohamed E. [4 ]
Teintze, Martin [1 ]
机构
[1] Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA
[2] Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA
[3] LSU Hlth Sci Ctr, Dept Pediat, Orleans, LA 70118 USA
[4] Novallux Biosci Inc, Princeton, NJ 08540 USA
关键词
Human immunodeficiency virus; Co-receptor; CXCR4; Guanide; Inhibitor; CHEMOKINE RECEPTOR CXCR4; SMALL-MOLECULE; ANTAGONISTS; T140; POTENT; IDENTIFICATION; CCR5;
D O I
10.1016/j.bmcl.2013.01.107
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The G-protein coupled receptor CXCR4 is a co-receptor for HIV-1 infection and is involved in signaling cell migration and proliferation. In a previous study of non-peptide, guanide-based CXCR4-binding compounds, spermine and spermidine phenylguanides inhibited HIV-1 entry at low micromolar concentrations. Subsequently, crystal structures of CXCR4 were used to dock a series of naphthylguanide derivatives of the polyamines spermidine and spermine. Synthesis and evaluation of the naphthylguanide compounds identified our best compound, spermine tris-1-naphthylguanide, which bound CXCR4 with an IC50 of 40 nM and inhibited the infection of TZM-bl cells with X4, but not R5, strains of HIV-1 with an IC50 of 50-100 nM. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2197 / 2201
页数:5
相关论文
共 24 条
[1]   Antigenically distinct conformations of CXCR4 [J].
Baribaud, F ;
Edwards, TG ;
Sharron, M ;
Brelot, A ;
Heveker, N ;
Price, K ;
Mortari, F ;
Alizon, M ;
Tsang, M ;
Doms, RW .
JOURNAL OF VIROLOGY, 2001, 75 (19) :8957-8967
[2]  
Carnec X., 1930, J VIROL, V2005, P79
[3]   Change in coreceptor use correlates with disease progression in HIV-1-infected individuals [J].
Connor, RI ;
Sheridan, KE ;
Ceradini, D ;
Choe, S ;
Landau, NR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (04) :621-628
[4]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732
[5]   CD4-independent infection by HIV-2 is mediated by Fusin/CXCR4 [J].
Endres, MJ ;
Clapham, PR ;
Marsh, M ;
Ahuja, M ;
Turner, JD ;
McKnight, A ;
Thomas, JF ;
StoebenauHaggarty, B ;
Choe, S ;
Vance, PJ ;
Wells, TNC ;
Power, CA ;
Sutterwala, SS ;
Doms, RW ;
Landau, NR ;
Hoxie, JA .
CELL, 1996, 87 (04) :745-756
[6]  
Frank R. L, 1955, ORG SYNTH, V3, P753
[7]   Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries [J].
Fujii, N ;
Oishi, S ;
Hiramatsu, K ;
Araki, T ;
Ueda, S ;
Tamamura, H ;
Otaka, A ;
Kusano, S ;
Terakubo, S ;
Nakashima, H ;
Broach, JA ;
Trent, JO ;
Wang, ZX ;
Peiper, SC .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (28) :3251-3253
[8]   Use of tissue culture cell lines to evaluate HIV antiviral resistance [J].
Krowicka, Halina ;
Robinson, James E. ;
Clark, Rebecca ;
Hager, Shannon ;
Broyles, Stephanie ;
Pincus, Seth H. .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (07) :956-966
[9]   GENETIC-ANALYSIS OF HIV-1 ISOLATES FROM BRAZIL REVEALS PRESENCE OF 2 DISTINCT GENETIC SUBTYPES [J].
LOUWAGIE, J ;
DELWART, EL ;
MULLINS, JI ;
MCCUTCHAN, FE ;
EDDY, G ;
BURKE, DS .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (05) :561-567
[10]   Immunological characteristics associated with the protective efficacy of antibodies to ricin [J].
Maddaloni, M ;
Cooke, C ;
Wilkinson, R ;
Stout, AV ;
Eng, L ;
Pincus, SH .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6221-6228